OBJECTIVES: The aim of the study was to determine whether the incidence of first-line treatment discontinuations and their causes changed according to the time of starting highly active antiretrovial therapy (HAART) in an Italian cohort. METHODS: We included in the study patients from the Italian Cohort Naive Antiretrovirals (ICoNA) who initiated HAART when naive to antiretroviral therapy (ART). The endopoints were discontinuation within the first year of >or=1 drug in the first HAART regimen for nay reason, intolerance/toxicity, poor adherence, immunovirological/clinical failure and simplification. We investigated whether the time of starting HAART (stratified as "early" 1997-1999; "intermediate", 2000-2002; "recent" 2003-2007) was associated with the probability of reaching the endpoints by a survival analysis. RESULTS: Overall, the 1-year probability of discontinuation of >or=1 drug in the first regimen was 36.1%. The main causes of discontiuation were intolerance /toxicity (696 of 1189 patients; 58.5%) and poor adherence (285 of 1189 patients, 24%). The hazards for all-reason change were comparable according to calendar period (2000-2002, adjusted relative hazard (ARH) 0.82, 95% confidence interval (CI) 0.69-0.98; 2003-2007, ARH 0.94, 95% CI 0.76-1-16, vs 1997-1999; global P-value = 0.08). Patients who started HAART during the "recent" period were less likely to change ther initial regimen because of intolerance/toxicity (ARH 0.67, 95% CI 0.51-0.89 vs "early" period). Patients who started in the "intermediate" and "recent" periods had a higher risk of discontinuation because of simplification (ARH 15.26, 95% CI 3.21-72.45, and ARH 37.97, 95% CI 7.56-190.64, vs. "early" period, respectively). CONCLUSIONS: It seems important to evaluate reason-specific trends in the incidence of discontinuation in order to better understand the determinants of changes over time. The incidence of discontinuation because of intolerance/toxicity has declined over time while simplification strategies have become more frequent in recent years. Intolerance/toxicity remains the major cause of drug discontinuation.

Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients.

FILICE, GAETANO;
2010-01-01

Abstract

OBJECTIVES: The aim of the study was to determine whether the incidence of first-line treatment discontinuations and their causes changed according to the time of starting highly active antiretrovial therapy (HAART) in an Italian cohort. METHODS: We included in the study patients from the Italian Cohort Naive Antiretrovirals (ICoNA) who initiated HAART when naive to antiretroviral therapy (ART). The endopoints were discontinuation within the first year of >or=1 drug in the first HAART regimen for nay reason, intolerance/toxicity, poor adherence, immunovirological/clinical failure and simplification. We investigated whether the time of starting HAART (stratified as "early" 1997-1999; "intermediate", 2000-2002; "recent" 2003-2007) was associated with the probability of reaching the endpoints by a survival analysis. RESULTS: Overall, the 1-year probability of discontinuation of >or=1 drug in the first regimen was 36.1%. The main causes of discontiuation were intolerance /toxicity (696 of 1189 patients; 58.5%) and poor adherence (285 of 1189 patients, 24%). The hazards for all-reason change were comparable according to calendar period (2000-2002, adjusted relative hazard (ARH) 0.82, 95% confidence interval (CI) 0.69-0.98; 2003-2007, ARH 0.94, 95% CI 0.76-1-16, vs 1997-1999; global P-value = 0.08). Patients who started HAART during the "recent" period were less likely to change ther initial regimen because of intolerance/toxicity (ARH 0.67, 95% CI 0.51-0.89 vs "early" period). Patients who started in the "intermediate" and "recent" periods had a higher risk of discontinuation because of simplification (ARH 15.26, 95% CI 3.21-72.45, and ARH 37.97, 95% CI 7.56-190.64, vs. "early" period, respectively). CONCLUSIONS: It seems important to evaluate reason-specific trends in the incidence of discontinuation in order to better understand the determinants of changes over time. The incidence of discontinuation because of intolerance/toxicity has declined over time while simplification strategies have become more frequent in recent years. Intolerance/toxicity remains the major cause of drug discontinuation.
2010
The Clinical Immunology & Infectious Diseases category covers resources that focus on basic research in clinical and applied allergy, immunology, and infectious disease. Microbiology and virology resources are included in this category as are resources on HIV, AIDS, sexually transmitted diseases (STDs), and hospital infections.
Nessuno
11
2
104
113
12
info:eu-repo/semantics/article
262
Cicconi, P.; Cozzi Lepri, A.; Castagna, A.; Trecarichi, E. M.; Antinori, A.; Gatti, F.; Cassola, G.; Sighinolfi, L.; Castelli, P.; d'Arminio Monforte,...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/810633
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact